Iacono 2015.

Study characteristics
Methods	Study design: parallel‐group randomized trial Study dates: not available Setting: outpatient, single center, national Country: Italy
Participants	Inclusion criteria: men affected by lower urinary tract symptoms due to BPH Exclusion criteria: not specified Sample size: 185 participants Age (years): mean 64.5 (SD 8.6) IPSS score (baseline): Group 1 (SD): 20.6 (5.4) Group 2 (SD): not available Prostate size: not available
Interventions	Group 1 (n = 95): Tramaxadina (Alga Ecklonia bicylis 80 mg, Tribulus terrestris 100 mg, chitosan oligosaccharide (Biovis) 100 mg) and Serenoa repens 320 mg daily for 6 months Group 2 (n = 90): placebo
Outcomes	Urinary symptoms How measured: IPSS Time points measured: not reported Time points reported: 6 months (only for the intervention group)
Notes	Funding sources: not available Conflict of interest: not available Study available only as an abstract of the 17th Annual Congress of the European Society for Sexual Medicine, 2015 February 5‐7; Copenhagen.